KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Insight, Inc., a leading U.S. developer of wearable medical devices and diagnostic software, announced today the company will showcase its one-of-a-kind cardiac devices and software systems, featuring proprietary algorithms, for the first time at a major cardiology exposition at the annual American College of Cardiology’s (ACC) 67th Annual Scientific Session and Expo. The show will be held March 10-12, 2018, at the Orange County Convention Center in Orlando, Florida. (https://accscientificsession.acc.org). The ACC.18 event is designed to share knowledge and innovation as a means to educate and help transform cardiovascular care and improve heart health.
Cardiac Insight will present interactive demonstrations of its Cardea SOLO™ and Cardea 20/20 ECG™ systems in the ACC.18 main convention hall, Booth #2417 and as one of the featured exhibitors inside the “Future Hub,” Booth #3517, which will consist of 15 cardiology companies highlighted from the more than 280 exhibiting at this year’s Expo. The Future Hub will present hands-on demonstrations, lectures and introductions to emerging innovations in cardiology.
“We look forward to sharing our revolutionary ECG devices and software to some of the best minds and organizations in the cardiology community,” said Chief Executive Officer Brad Harlow. “Our company’s cardiac technology and products are gaining recognition by some of the world’s top cardiologists for their differentiated capabilities that facilitate frontline cardiac diagnosis. ACC.18 will help ensure that more cardiology professionals worldwide experience our innovations and witness, firsthand, how Cardiac Insight’s solutions, based on offering advanced body-worn biosensors with smart PC-based analysis systems, are unrivaled in the industry.”
Cardiac Insight’s ECG devices and software are designed to target two distinct and significant healthcare market needs: Cardea SOLO is a wearable, cable-free, 7-day ECG sensor and PC-based analysis system for the detection of adult cardiac arrhythmias, including atrial fibrillation or AFib. Cardea 20/20 ECG is the only 12-lead ECG system engineered to identify the risk of Sudden Cardiac Arrest in young athletes.
“One of our main differentiators is our proprietary software, containing advanced arrhythmia detection algorithms, which makes it possible for physicians to take control of their patient’s ECG data and the diagnostic process right in their office-based practice,” added Harlow. “As in the case of Cardea SOLO, it is the ONLY in-office ECG analysis software cleared by the FDA to produce an automated draft report without human intervention, ready for clinician review or edits in five minutes or less.”
About Cardiac Insight, Inc.
Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. developer of advanced body-worn digital health care information systems through its proprietary software, algorithms and devices. The company’s two flagship products are the wearable ECG sensor, Cardea SOLO™ (www.cardeasolo.com) and Cardea 20/20 ECG™. The company was founded in 2008 and is based in Kirkland, Washington.
